{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:36:01Z","timestamp":1784306161520,"version":"3.55.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2021,1,2]]},"DOI":"10.1080\/14737175.2021.1834383","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T18:23:27Z","timestamp":1602095007000},"page":"99-110","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[{"name":"Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[{"name":"Health Agency of Tuscany, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Science of Health, University of Catanzaro, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"La Neve","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Anna Maria","family":"Lodi","sequence":"additional","affiliation":[{"name":"Department of Child Neuropsychiatry, Epilepsy Center, Fatebenefratelli Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-1476","authenticated-orcid":false,"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[{"name":"Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, \u201cG. Gaslini\u201d Institute, University of Genoa, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252807.38124.a3"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13025"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91208-8"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.cophys.2017.12.007"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1086\/320609"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000069463.41870.2F"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03177.x"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb04593.x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3188-y"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.14581\/jer.17012"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01171-4"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0377-3"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00708-6"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0558-9"},{"key":"cit0016","unstructured":"FDA. Drug approval package: epidiolex (cannabidiol), NDA 210365, FDA center for drug evaluation and research. [cited Jul 2020]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210365Orig1s000TOC.cfm."},{"key":"cit0017","unstructured":"European Medicines Agency. Assessment report: epidyolex. International non-proprietary name: cannabidiol. [cited Jul 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/epidyolex-epar-public-assessment-report_en.pdf."},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14628"},{"key":"cit0019","volume-title":"The American Epilepsy Society Annual Meeting","author":"Marsh ED","year":"2017"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2019.03.015"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0578-5"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16419"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12631"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1089\/can.2015.0012"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2011.05.018"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041384"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16093"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90386-G"},{"key":"cit0029","unstructured":"FDA briefing document. Peripheral and central nervous system drugs. Advisory Committee Meeting. NDA210365. Cannabidiol. 2018 Apr 19 [cited Jul 2020]. Available from: https:\/\/www.fda.gov\/media\/112565\/download."},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.665"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13060"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16546"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16607"},{"issue":"1","key":"cit0034","first-page":"16","volume":"22","author":"Landmark CJ","year":"2020","journal-title":"Epileptic Disord"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00726-4"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16596"},{"key":"cit0037","unstructured":"Morrison G, Taylor L, Crockett J, et al. A phase 1 investigation into the potential effects of cannabidiol on CYP3A4-mediated drug-drug interactions. Abstract presented at AES 2018 (Abst. 1.297). [cited Jul 2020]. Available from: https:\/\/www.aesnet.org\/sites\/default\/files\/file_attach\/AES%20abstract-%20FINAL-low-resolution.pdf."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13852"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16071"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0921"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0992-5"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2019.55.3.2909248"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.04.044"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.04.008"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1080\/19390211.2020.1761506"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0589-2"},{"key":"cit0047","unstructured":"Epidiolex (cannabidiol) oral solution \u2013 highlights of prescribing information. [cited Jul 2020]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.3.7.589"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13249"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6613"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00359"},{"key":"cit0052","volume-title":"The American Epilepsy Society Annual Meeting","author":"Thiele E","year":"2019"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.05.013"},{"key":"cit0054","doi-asserted-by":"crossref","unstructured":"Lattanzi S, Trinka E, Striano P, et al. Cannabidiol oral solution: a new class of antiseizure medications. European Neurological Review. 2020; 15.","DOI":"10.17925\/ENR.2020.15.1.19"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2021.1834383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T12:49:56Z","timestamp":1669121396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2021.1834383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,2]]}},"alternative-id":["10.1080\/14737175.2021.1834383"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2021.1834383","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}